Stocks of Tango Therapeutics Inc (NASDAQ:TNGX) traded higher last session on Wall Street, up 21.37% to $4.26.
TNGX stock price is now 152.49% away from the 50-day moving average and 5.55% away from the 200-day moving average. The market capitalization of the company currently stands at $461.76M.
With the price target of $19, Jefferies recently initiated with Buy rating for Tango Therapeutics Inc (NASDAQ: TNGX). , while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Barry Douglas, General Counsel sold 2,774 shares of the company’s stock on Feb 04 ’25. The stock was sold for $8,289 at an average price of $2.99. Upon completion of the transaction, the General Counsel now directly owns 68,570 shares in the company, valued at $0.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 05 ’25, General Counsel Barry Douglas sold 2,556 shares of the business’s stock. A total of $8,081 was realized by selling the stock at an average price of $3.16. This leaves the insider owning 66,014 shares of the company worth $0.28 million. A total of 45.64% of the company’s stock is owned by insiders.
During the past 12 months, Tango Therapeutics Inc has had a low of $1.03 and a high of $12.02. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 6.26, and a quick ratio of 6.26.
The net profit margin was -322.67% and return on equity was -61.35% for TNGX. The company reported revenue of $5.39 million for the quarter, compared to $6.47 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.67 percent.
